|
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. |
50.00% |
|
Retrospective study of Ukrain treatment in 203 patients with advanced-stage tumors |
90.00% |
|
Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone |
100.00% |
|
Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo |
70.00% |
|
Review on molecular and therapeutic potential of thymoquinone in cancer. |
60.00% |
|
Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. |
60.00% |
|
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic ca |
90.00% |
|
Role of everolimus in the treatment of renal cell carcinoma. |
50.00% |
|
Role of infectious agents in the emergence of malignant tumors |
90.00% |
|
Roles of sildenafil in enhancing drug sensitivity in cancer. |
50.00% |
|
ROS production and angiogenic regulation by macrophages in response to heat therapy. |
80.00% |
|
Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial |
70.00% |
|
Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. |
90.00% |
|
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. |
50.00% |
|
Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins |
80.00% |
|
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. |
80.00% |
|
Sanguinarine-induced apoptosis in human leukemia U937 cells via Bcl-2 downregulation and caspase-3 activation. |
90.00% |
|
Selective inhibition of in vitro cell growth by the anti-tumour drug Ukrain |
70.00% |
|
Sen. Ron Johnson Sends Letter to Sec. of Defense Demanding Information on Shockingly High COVID-19 Vaccine Injury Among Military Personnel |
100.00% |
|
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. |
80.00% |
|
Serum calcium and the risk of prostate cancer. |
60.00% |
|
Serum cytokines in pancreatic cancer: Correlation with outcome |
40.00% |
|
Six-week treatment with Ukrain in rabbits. Part III: Serum levels of thyroid hormones |
|
|
Some pharmacological properties of prolonged administration of Ukrain in rodents |
50.00% |
|
SONIA POULTON INTERVIEWS DR. MIKAEL NORDFORS CORRUPTED MEDICINE AND ALTERNATIVE TREATMENTS. |
70.00% |
|
Stoppa Massmordet! |
100.00% |
|
Strong synergy of heat and modulated electromagnetic field in tumor cell killing. |
60.00% |
|
Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes |
70.00% |
|
Survivin and pancreatic cancer. |
60.00% |
|
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and |
60.00% |
|
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. |
60.00% |
|
Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. |
70.00% |
|
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growt |
80.00% |
|
Systematic review of the treatment of cancer-associated anorexia and weight loss. |
60.00% |
|
Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. |
50.00% |
|
Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for NSCLC. |
70.00% |
|
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer. |
90.00% |
|
Systems biology: a therapeutic target for tumor therapy. |
86.67% |
|
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer |
70.00% |
|
Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. |
30.00% |
|
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines |
70.00% |
|
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Onco |
40.00% |
|
Teratological evaluation of Ukrain in hamsters and rats |
|
|
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse |
80.00% |
|
The anti-angiogenic basis of metronomic chemotherapy. |
85.00% |
|
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking and |
80.00% |
|
The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro. |
80.00% |
|
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline |
70.00% |
|
The dynamics of concentration of the main fluorescent component of Ukrain in the tissues and blood plasma of rats with W-256 ... |
80.00% |
|
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. |
80.00% |
|
The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways |
70.00% |
|
The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky |
60.00% |
|
The efficacy of corticosteroids in restoring hearing in patients undergoing conservative management of acoustic neuromas.' |
70.00% |
|
The emerging low-dose therapy for advanced cancers. |
80.00% |
|
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary stu |
60.00% |
|
The immunomodulating preparation Ukrain does not induce anaphylactic sensitization in mice and guinea pigs |
20.00% |
|
The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. |
80.00% |
|
The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing |
|
|
The influence of glucose, succinate, pH of the medium and higher temperature on the cytotoxic activity of the preparation Ukrain |
80.00% |
|
The influence of the novel drug Ukrain on hemo- and immunopoiesis at the time of its maximum radioprotective effect |
60.00% |
|
The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy |
30.00% |
|
The inhibition of glioma growth in vitro and in vivo by a chitosan/ellagic acid composite biomaterial. |
70.00% |
|
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alp |
90.00% |
|
The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. |
80.00% |
|
The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications |
90.00% |
|
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. |
90.00% |
|
The present state of antineoplaston research (1) |
90.00% |
|
The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness |
60.00% |
|
The story of the cancer medicine Ukrain and Wassil Nowicky |
55.00% |
|
The use of mushroom glucans and proteoglycans in cancer treatment. |
90.00% |
|
The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhib |
|
|
The way ‘Covid deaths’ are being counted is a national scandal |
80.00% |
|
Theoretical grounds and experimental confirmation of the antiviral effect of the |
60.00% |
|
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carci |
|
|
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. |
60.00% |
|
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in ........ |
90.00% |
|
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. |
50.00% |
|
Todoxin, the immune stimulant from Serbia |
86.36% |
|
Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expressio |
80.00% |
|
Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. |
80.00% |
|
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. |
50.00% |
|
Trans Arterial Chemo Embolization(TACE) |
40.00% |
|
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecula |
80.00% |
|
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. |
90.00% |
|
Treatment of locally advanced pancreatic cancer with concurrent uftoral and radiotherapy. Results from 64 patients treated from |
80.00% |
|
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. |
80.00% |
|
Tumor pO(2) as a Surrogate Marker to Identify Therapeutic Window during Metronomic Chemotherapy of 9L Gliomas. |
60.00% |
|
Tumor therapy with Amanita phalloides (death cap): stabilization of B-cell chronic lymphatic leukemia. |
90.00% |
|
Tumoral angiogenesis: review of the literature. |
50.00% |
|
Ukrain |
62.22% |
|
Ukrain - a new cancer cure? A systematic review of randomised clinical trials. |
90.00% |
|
Ukrain acts by inhibition of tubulin polymerization in normal and malignant cell lines. |
80.00% |
|
Ukrain both as an anti cancer and immunoregulatory agent |
60.00% |
|
Ukrain Debate 1: What is the active Substance of Ukrain? |
80.00% |
|
Ukrain in the treatment of urethral recurrent carcinoma (case report) |
50.00% |
|
Ukrain monotherapy in malignant melanoma (case report) |
80.00% |
|
Ukrain therapy in a frontal anaplastic grade III astrocytoma (case report) |
40.00% |
|
Ukrain therapy of a recurrent astrocytoma of the optic nerve (case report) |
20.00% |
|
Ukrain therapy of recurrent breast cancer with lung metastases (case report) |
80.00% |
|
Ukrain therapy of stage T1N0M0 bladder cancer patients |
60.00% |
